JP2008518974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518974A5 JP2008518974A5 JP2007539372A JP2007539372A JP2008518974A5 JP 2008518974 A5 JP2008518974 A5 JP 2008518974A5 JP 2007539372 A JP2007539372 A JP 2007539372A JP 2007539372 A JP2007539372 A JP 2007539372A JP 2008518974 A5 JP2008518974 A5 JP 2008518974A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- long chain
- nkt cell
- composition according
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000581 natural killer T-cell Anatomy 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 230000020411 cell activation Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 2
- 150000001414 amino alcohols Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 150000003333 secondary alcohols Chemical class 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- 206010013710 Drug interaction Diseases 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 238000010171 animal model Methods 0.000 claims 1
- POQRWMRXUOPCLD-HIIAJUEOSA-N beta-D-galactosyl-N-(tetracosanoyl)sphingosine Chemical group CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O POQRWMRXUOPCLD-HIIAJUEOSA-N 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62456804P | 2004-11-02 | 2004-11-02 | |
| US60/624,568 | 2004-11-02 | ||
| US70654805P | 2005-08-08 | 2005-08-08 | |
| US60/706,548 | 2005-08-08 | ||
| PCT/US2005/040182 WO2006060117A2 (en) | 2004-11-02 | 2005-11-02 | Methods for inhibition of nkt cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008518974A JP2008518974A (ja) | 2008-06-05 |
| JP2008518974A5 true JP2008518974A5 (https=) | 2008-11-27 |
| JP4948418B2 JP4948418B2 (ja) | 2012-06-06 |
Family
ID=36565493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539372A Expired - Fee Related JP4948418B2 (ja) | 2004-11-02 | 2005-11-02 | Ｎｋｔ細胞を抑制するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7682614B2 (https=) |
| EP (1) | EP1812015B1 (https=) |
| JP (1) | JP4948418B2 (https=) |
| CN (1) | CN101031307B (https=) |
| AT (1) | ATE539757T1 (https=) |
| AU (1) | AU2005310247A1 (https=) |
| CA (1) | CA2584971C (https=) |
| DK (1) | DK1812015T3 (https=) |
| ES (1) | ES2378076T3 (https=) |
| PT (1) | PT1812015E (https=) |
| WO (1) | WO2006060117A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1372668B1 (en) | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| WO2011149881A2 (en) * | 2010-05-24 | 2011-12-01 | Children's Medical Center Corporation | Methods for the treatment and prevention of inflammatory diseases |
| RU2603075C2 (ru) * | 2010-11-25 | 2016-11-20 | Имнейт Сарл | Изменение иммуногенности антигена путем введения эпитопов, узнаваемых nkt-клетками |
| US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
| JP2015502340A (ja) * | 2011-10-27 | 2015-01-22 | エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ｉＮＫＴに対するヒト化抗体 |
| EP2906576B1 (en) * | 2012-10-12 | 2019-09-11 | The Brigham and Women's Hospital, Inc. | Glycosphingolipids and methods of use thereof |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| AU2013388034B2 (en) | 2013-04-30 | 2019-08-15 | Aspeya US Inc. | Dry powder formulations and methods of use |
| US10501541B2 (en) | 2015-01-27 | 2019-12-10 | Lava Therapeutics B.V. | Single domain antibodies targeting CD1d |
| JP6918365B2 (ja) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 脂質化ｐｓａ組成物および方法 |
| US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| JP7493449B2 (ja) | 2017-09-22 | 2024-05-31 | ヴェクチュラ インコーポレイテッド | ステアリン酸マグネシウムを含む乾燥粉末組成物 |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| AU2019344300A1 (en) | 2018-09-19 | 2021-04-22 | LAVA Therapeutics N.V. | Dual acting CD1D immunoglobulin |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
| JPWO2023153527A1 (https=) * | 2022-02-14 | 2023-08-17 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US7063844B2 (en) | 1992-12-10 | 2006-06-20 | The Brigham And Women's Hospital, Inc. | Presentation of hydrophobic antigens to T-cells by CD1 molecules |
| US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
| EP0751780B1 (en) | 1993-06-21 | 2003-09-03 | Brigham And Women's Hospital | Methods of isolating cd1-presented antigens, vaccines comprising cd1-presented antigens, and cell lines for use in said methods |
| US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| JP3495740B2 (ja) | 1997-04-10 | 2004-02-09 | 麒麟麦酒株式会社 | α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤 |
| EP1011719A1 (en) | 1997-09-12 | 2000-06-28 | Brigham & Women's Hospital | Synthetic antigens for cd1-restricted immune responses |
| TW575420B (en) | 1997-09-22 | 2004-02-11 | Kirin Brewery | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| EP1095062B1 (en) | 1998-07-09 | 2006-09-13 | Brian J. Nickoloff | Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| US20010051156A1 (en) | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
| US20020071842A1 (en) | 2000-06-05 | 2002-06-13 | Gumperz Jenny E. | Soluble CD1 compositions and uses thereof |
| EP1288291A4 (en) | 2000-06-06 | 2004-05-12 | Kirin Brewery | METHOD FOR REPLACING NATURAL KILLER T CELLS |
| JP5184732B2 (ja) * | 2000-06-19 | 2013-04-17 | ベス イスラエル デアコネス メディカル センター | Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法 |
| WO2001098317A2 (en) | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| JP3986957B2 (ja) | 2000-08-18 | 2007-10-03 | 三菱電機株式会社 | ランプ用トランス |
| DE10046658A1 (de) | 2000-09-20 | 2002-04-04 | Bosch Gmbh Robert | Induktiver Übertrager und ein Verfahren zu dessen Herstellung |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| IL140537A0 (en) | 2000-12-25 | 2002-02-10 | Hadasit Med Res Service | Educated nk t cells and their uses in the treatment of immune-related disorders |
| EP1372668B1 (en) * | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| US6662434B2 (en) | 2001-04-03 | 2003-12-16 | General Electric Company | Method and apparatus for magnetizing a permanent magnet |
| US8178098B2 (en) * | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| US20030064967A1 (en) | 2001-04-11 | 2003-04-03 | Jayraz Luchoomun | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters |
| US20020171538A1 (en) | 2001-05-15 | 2002-11-21 | Kuo-Hsin Su | Vehicle motion detector and control device arrangement |
| US20020171557A1 (en) | 2001-05-18 | 2002-11-21 | Wegener William E. | Security electronic system |
| EP1434859A2 (en) | 2001-07-25 | 2004-07-07 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| US8084020B2 (en) | 2002-05-01 | 2011-12-27 | Beth Israel Deaconess Medical Center | Use of anti-CD1 antibodies for the modulation of immune responses |
| AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| ES2365210T3 (es) | 2002-06-14 | 2011-09-26 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health | Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales. |
| US7368142B2 (en) | 2002-08-01 | 2008-05-06 | Renew Life Formulas, Inc. | Natural sweetener |
| WO2004019900A1 (en) | 2002-08-27 | 2004-03-11 | Societe Des Produits Nestle | Preventing or treating epithelial tissue damage or hair loss |
| AU2003277021A1 (en) | 2002-09-27 | 2004-04-19 | Biomira, Inc. | Glycosylceramide analogues |
| US20040171522A1 (en) | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
| WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| US9717754B2 (en) * | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| US20040235162A1 (en) | 2003-03-18 | 2004-11-25 | Kirin Beer Kabushiki Kaisha | Method of preparing immunoregulatory dendritic cells and the use thereof |
| US20050032210A1 (en) | 2003-03-18 | 2005-02-10 | Kirin Beer Kabushiki Kaisha | Method of preparing immuno-regulatory dendritic cells and the use thereof |
| AU2003225891A1 (en) | 2003-03-20 | 2004-11-19 | Brigham Young University | 6"-amino-6"-deoxygalactosylceramides |
| WO2004084874A2 (en) | 2003-03-24 | 2004-10-07 | Brigham And Women's Hospital, Inc. | Mtp inhibitors for inhibiting inflammation |
| EP1653977A2 (en) | 2003-07-17 | 2006-05-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Treatment of disorders associated with natural killer t cells |
| EP1767216B1 (en) * | 2004-06-11 | 2012-07-11 | Riken | Drug having regulatory cell ligand contained in liposome |
-
2005
- 2005-11-02 WO PCT/US2005/040182 patent/WO2006060117A2/en not_active Ceased
- 2005-11-02 EP EP05851383A patent/EP1812015B1/en not_active Expired - Lifetime
- 2005-11-02 ES ES05851383T patent/ES2378076T3/es not_active Expired - Lifetime
- 2005-11-02 JP JP2007539372A patent/JP4948418B2/ja not_active Expired - Fee Related
- 2005-11-02 US US11/266,033 patent/US7682614B2/en not_active Expired - Fee Related
- 2005-11-02 AU AU2005310247A patent/AU2005310247A1/en not_active Abandoned
- 2005-11-02 CN CN2005800330994A patent/CN101031307B/zh not_active Expired - Fee Related
- 2005-11-02 DK DK05851383.9T patent/DK1812015T3/da active
- 2005-11-02 CA CA2584971A patent/CA2584971C/en not_active Expired - Fee Related
- 2005-11-02 PT PT05851383T patent/PT1812015E/pt unknown
- 2005-11-02 AT AT05851383T patent/ATE539757T1/de active
-
2010
- 2010-02-01 US US12/697,882 patent/US8679499B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518974A5 (https=) | ||
| Chen et al. | Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury | |
| Luo et al. | Neuroprotection against focal ischemic brain injury by the peroxisome proliferator‐activated receptor‐γ agonist rosiglitazone | |
| US10639301B2 (en) | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug | |
| Ohnishi et al. | HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats | |
| Garau et al. | Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia | |
| Nordgren et al. | Docosahexaenoic acid enhances amphiregulin-mediated bronchial epithelial cell repair processes following organic dust exposure | |
| JP2016525140A5 (https=) | ||
| Tang et al. | Conjugated linoleic acid attenuates 2, 4-dinitrofluorobenzene-induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-κB signaling | |
| BRPI0412909A (pt) | uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer | |
| Díaz-Perales et al. | The role of sphingolipids in allergic disorders | |
| MX395136B (es) | Composiciones farmaceuticas y metodos de administracion relacionados. | |
| BRPI0608205A2 (pt) | derivado heterocìclico-1-carboxilato de piridila não-aromático nitrogenado | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| JP2010518029A5 (https=) | ||
| BR0014946A (pt) | Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina | |
| JP2018501312A (ja) | ノカルダミンの新規金属錯体および医薬組成物におけるそれらの使用 | |
| Padmanaban et al. | Curcumin may defy medicinal chemists | |
| Tollesson et al. | Malassezia furfur in infantile seborrheic dermatitis | |
| WO2022256291A1 (en) | Hydrogel devices for drug delivery to the ear | |
| Beray-Berthat et al. | Long-term histological and behavioural characterisation of a collagenase-induced model of intracerebral haemorrhage in rats | |
| Yanık et al. | Current neuroprotective agents in stroke | |
| FR3130140B1 (fr) | Agent de traitement capillaire avec effet de soin amélioré | |
| Strosznajder et al. | Effects of p53 inhibitor on survival and death of cells subjected to oxidative stress | |
| Nabe et al. | Involvement of chymase in allergic conjunctivitis of guinea pigs |